Inovio Pharmaceuticals Inc (INO): “As part of DARPA's two-year grant,...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	3218
Boards Moderated	0
Alias Born	04/26/2007

Lakers_w

Re: None

Wednesday, 10/20/2021 4:13:02 PM

Wednesday, October 20, 2021 4:13:02 PM

“As part of DARPA's two-year grant, INOVIO and Wistar teams will construct COVID-19 dMAb candidates mirroring AZN’s traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19. dMAb candidates can be quickly developed and produced in vivo, offering a cost-effective and scalable therapeutic and preventive option for treatment of SARS-CoV-2 virus infection. The dMAb candidates will then be advanced into preclinical studies and then into rigorous, first-in-human clinical trials within one year of funding.” 12/15/20

COVID-19 dMAb P1/P2 to start before 12/15/21.

10/5 AZN seeks EUA for AZD7442 also being dMAb®-cloned by Ino
Under DARPA’s two-year grant, INOVIO and Wistar teams will construct COVID-19 dMAb candidates designed to mirror AZN’s traditional recombinant monoclonal antibody candidates now being tested in clinical trials to treat COVID-19, such as AZD7442.

https://news.vumc.org/2021/10/05/astrazeneca-seeks-emergency-approval-for-covid-19-antibodies-isolated-at-vumc/
https://www.genengnews.com/covid-19-candidates/inovio-pharmaceuticals-and-astrazeneca-dmabs/